哈药集团股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600664 证券简称：哈药股份 编号：临 2025-036 哈药集团股份有限公司（以下简称"公司"）控股股东哈药集团 有限公司（以下简称"哈药集团"）持有公司股份 1,173,237,023 股，占 本公司总股本的 46.58%；本次解除质押及再质押完成后，哈药集团累计 质押股份 926,857,248 股，占其所持有公司股份总数的 79.00%，占公司总 股本的 36.80%。 公司于近日收到哈药集团的告知函，获悉其所持有的 148,571,428 股 公司股份办理了解除质押及再质押登记手续，现将有关情况公告如下： 一、本次股份解除质押情况 哈药集团原质押给中国银行股份有限公司澳门分行的部分公司股份已 经办理完成了解除质押手续，具体如下： | 股东名称 | 哈药集团有限公司 | | --- | --- | | 本次解除质押股份（股） | 148,571,428 | | 占其所持股份比例 ...

Group 1 - The core point of the article highlights the recent performance of Harbin Pharmaceutical Group Co., Ltd. (哈药股份), noting a stock price of 3.92 yuan, a decrease of 2.97% as of August 25, 2025 [1] - The company reported total revenue of 8.125 billion yuan for the first half of 2025, a year-on-year decrease of 0.21%, and a net profit attributable to shareholders of 260 million yuan, down 24.37% year-on-year [1] - The company's liquidity ratios include a current ratio of 1.440 and a quick ratio of 1.179, with a debt-to-asset ratio of 54.71% [1] Group 2 - Harbin Pharmaceutical Group has made investments in 30 companies and participated in 3,232 bidding projects [2] - The company holds 2 trademark registrations and 67 patents, along with 21 administrative licenses [2]

证券研究报告 哈药股份 (600664 CH) 核心业务收入平稳，净利率有所波动 2025 年 8 月 25 日│中国内地 化学制药 公司公告 1H25 业绩，营收、归母净利、扣非净利 81.2/2.6/2.4 亿元 （-0%/-24%/-22% yoy），其中 2Q25 分别同比下滑 1%/72%/74%，利润 下滑主因工业毛利率下降、商业利润下滑及资产计提减值。我们认为药店 行业承压下公司收入保持韧性，季度利润因费用有所波动，我们看好随着 药店行业企稳恢复与公司营销调整结束，公司利润与品牌价值释放，维持 "买入"评级。 工业收入：核心业务保持平稳，电商业务有所下滑 因药店行业整体承压（米内网数据显示 1H25 中国实体药店药品零售规模同 比下滑 0.9%、保健品零售规模同比下滑 18.6%）及公司策略调整（探索高 效投放模式），工业收入 1H25 同比下滑 6%至 29.8 亿元（其中 2Q25 同比 下滑 9%至 14.7 亿元），其中主营 OTC 的营销公司收入同比下滑 4%至 13.6 亿元，主营保健品的 GNC 中国收入同比增长 3%至 7.4 亿元，主营电商渠 道的健康科技收入同比下滑 30%至 ...

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Core Viewpoint - Haoyao Group Co., Ltd. has shown a net financing inflow of 31.4015 million yuan last week, ranking 416th in the market, indicating a moderate interest from investors [1] Financing and Investment Summary - The total financing amount for Haoyao Group last week was 177 million yuan, while the repayment amount was 145 million yuan [1] - Over the past 5 days, the main capital outflow was 21.4667 million yuan, with a decline of 1.72% [1] - Over the past 10 days, the main capital outflow reached 60.8916 million yuan, with a decline of 2.71% [1] Company Profile - Haoyao Group Co., Ltd. was established in 1991 and is located in Harbin, primarily engaged in the pharmaceutical manufacturing industry [1] - The registered capital of the company is 25,212.78976 million yuan, and the paid-in capital is 25,072.19075 million yuan [1] - The legal representative of the company is Lu Chuanyou [1] Business Activities - Haoyao Group has invested in 30 enterprises and participated in 3,232 bidding projects [1] - The company holds 2 trademark registrations and 67 patents, along with 21 administrative licenses [1]

（文章来源：证券日报） 证券日报网讯 8月22日晚间，哈药股份发布公告称，2025年半年度公司实现营业收入8，124，702， 491.09元，同比下降0.21%；归属于上市公司股东的净利润为259，705，144.23元，同比下降24.37%。 ...

Group 1 - The company announced the approval of the full text and summary of the 2025 semi-annual report during the 17th meeting of the 10th board of directors [2]

（文章来源：证券日报） 证券日报网讯 8月22日晚间，哈药股份发布公告称，公司第十届监事会第七次会议审议通过了《2025年 半年度报告全文及摘要》等多项议案。 ...

Group 1 - The core point of the article is that Harbin Pharmaceutical Group Co., Ltd. plans to apply for an increase in credit limit of 1.55 billion yuan from financial institutions for the year 2025 [1] - The funds will be used for various financial services including but not limited to bank working capital loans, bank acceptance bills, domestic and foreign letters of credit, and guarantees [1]

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (600664.SH) reported a slight decline in revenue and a significant drop in net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 8.125 billion yuan, representing a year-on-year decrease of 0.21% [1] - The net profit attributable to shareholders of the listed company was 260 million yuan, down 24.37% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 244 million yuan, a decrease of 21.71% year-on-year [1] - Basic earnings per share were reported at 0.1 yuan [1]